Eli Lilly said an experimental triple agonist molecule helped participants with type 2 diabetes in a trial significantly reduce their A1C levels while also losing weight without a plateau. File Photo by Wael Hamzeh/EPA
March 19 (UPI) -- Eli Lilly's next generation obesity drug retatrutide helped significantly reduce A1C levels for people with diabetes while helping them lose weight without a plateau, the company announced.
Retatrutide, which would be Lilly's third obesity drug on the market if the Food and Drug Administration approves it, met both A1C- and weight-reduction goals in a Phase 3 trial of people with hard-to-control diabetes.
The company said the investigational GIP, GLP-1 glucagon triple hormone receptor agonist may offer another option for both diabetes and obesity.
"For many people with type 2 diabetes, it is a struggle to achieve both A1C control and weight loss, since obesity has historically been harder to treat for those with type 2 diabetes," Kenneth Custer, executive vice president and president of Lilly Cardiometabolic Health, said in a press release.
